erlotinib hydrochloride has been researched along with delphinidin in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (delphinidin) | Trials (delphinidin) | Recent Studies (post-2010) (delphinidin) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 250 | 3 | 156 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aichinger, G; Berger, W; Marko, D; Nagel, LJ; Pahlke, G | 1 |
1 other study(ies) available for erlotinib hydrochloride and delphinidin
| Article | Year |
|---|---|
Bilberry extract, its major polyphenolic compounds, and the soy isoflavone genistein antagonize the cytostatic drug erlotinib in human epithelial cells.
Topics: Anthocyanins; Cell Line, Tumor; Cytostatic Agents; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Gallic Acid; Genistein; Glucosides; Glycine max; Humans; Phloroglucinol; Phosphorylation; Plant Extracts; Polyphenols; Vaccinium myrtillus | 2016 |